莫西沙星与左氧氟沙星治疗老年慢性阻塞性肺疾病患者的临床疗效

Clinical efficacy of moxifloxacin and levofloxacin in the treatment of elderly patients with chronic obstructive pulmonary disease

目的探究莫西沙星与左氧氟沙星治疗老年慢性阻塞性肺疾病(慢阻肺)患者的临床疗效。方法选取2020年12月至2021年12月安陆市普爱医院收治的210例慢阻肺患者作为研究对象,随机分为对照组与观察组,每组105例。对照组给予左氧氟沙星治疗,观察组给予莫西沙星治疗,比较两组肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC]、血气分析指标[动脉血氧饱和度(SaO_(2))、动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]、不良反应发生情况及临床疗效。结果治疗后,两组FVC、FEV_(1)、FEV_(1)/FVC均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组SaO_(2)、PaO_(2)均高于治疗前,PaCO_(2)均低于治疗前,且观察组SaO_(2)、PaO_(2)均高于对照组,PaCO_(2)低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为3.81%,低于对照组的11.43%,差异有统计学意义(P<0.05)。观察组治疗总有效率为97.14%,高于对照组的90.48%,差异有统计学意义(P<0.05)。结论莫西沙星治疗老年慢阻肺疾病疗效确切,可明显改善患者肺功能及血气分析指标,且不良反应较少,值得临床推广应用。

Objective To explore the clinical efficacy of moxifloxacin and levofloxacin in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD).Methods A total of 210 COPD patients admitted to Anlu Puai Hospital from December 2020 to December 2021 were selected as the research subjects,and randomly divided into the control group and the observation group,with 105 cases in each group.The control group was given levofloxacin treatment,the observation group was given moxifloxacin treatment,the pulmonary function indexes(forced vital capacity[FVC],forced expiratory volume in one second[FEV_(1)],FEV_(1)/FVC),blood gas analysis indexes(arterial oxygen saturation[SaO_(2)],partial pressure of oxygen[PaO_(2)],partial pressure of carbon dioxide[PaCO_(2)]),occurrence of adverse reactions and clinical efficacy were compared between the two groups.Results After treatment,the FVC,FEV_(1) and FEV_(1)/FVC of the two groups were higher than those before treatment,and the observation group were higher than the control group,the differences were statistically significant(P<0.05).After treatment,the SaO_(2) and PaO_(2) of the two groups were higher than those before treatment,the PaCO_(2) was lower than that before treatment,and SaO_(2) and PaO_(2) in the observation group were higher than those in the control group,the PaCO_(2) was lower than that in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 3.81%,which was lower than 11.43%in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 97.14%,which was higher than 90.48%in the control group,and the difference was statistically significant(P<0.05).Conclusion Moxifloxacin is effective in the treatment of elderly patients with COPD,it can significantly improve the lung function and blood gas analysis indexes of patients,and has fewer adverse reactions,it is worthy of clinical application.